TG Therapeutics, Inc.
TGTX
Hisse Senetlerindeki Sıralama
#2355
Based in New York City and established in 1993, TG Therapeutics, Inc. is a... Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
Hisse Fiyatı
$54.70
Son senkronizasyon: 2026-10-20
Piyasa Değeri
$8.37B
Değişim (1 gün)
2.63%
Değişim (1 yıl)
55.31%
Ülke
US
Ticaret TG Therapeutics, Inc. (TGTX)
Kategori
Healthcare
TG Therapeutics, Inc. (TGTX) için kazanç
Jun 2026 itibarıyla kazanç TTM: $101.60M
TG Therapeutics, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $101.60M'dir. 2023 yılında şirket $13.06M kazanç elde etti, bu 2022 yılındaki $-223.81M kazanca göre önceki yıla göre artış. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
TG Therapeutics, Inc. için kazanç geçmişi 2000 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $101.60M | 296.96% |
| 2024 | $25.59M | 95.94% |
| 2023 | $13.06M | -105.84% |
| 2022 | $-223.81M | -35.70% |
| 2021 | $-348.10M | 24.60% |
| 2020 | $-279.38M | 61.61% |
| 2019 | $-172.87M | -0.35% |
| 2018 | $-173.48M | 46.43% |
| 2017 | $-118.48M | 51.40% |
| 2016 | $-78.25M | 24.31% |
| 2015 | $-62.95M | 12.85% |
| 2014 | $-55.78M | 172.39% |
| 2013 | $-20.48M | -20.79% |
| 2012 | $-25.85M | 2,807.86% |
| 2011 | $-889.07K | -166.04% |
| 2010 | $1.35M | -147.54% |
| 2009 | $-2.83M | -39.27% |
| 2008 | $-4.66M | -61.25% |
| 2007 | $-12.03M | 20.31% |
| 2006 | $-10.00M | -48.32% |
| 2005 | $-19.35M | 218.71% |
| 2004 | $-6.07M | -15.91% |
| 2003 | $-7.22M | 363.40% |
| 2002 | $-1.56M | -12.31% |
| 2001 | $-1.78M | -69.86% |
| 2000 | $-5.90M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | 5,091.88% |
US
|
|
| $-3.09B | -3,138.42% |
US
|
|
| $-4.02B | -4,052.99% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,819.95% |
NL
|
